Table 4. Treatment Association of the SEP-1 Bundle and Components With Mortality and Vasopressor Days in the Rebalanced Total Sample.
| Treatment | Mortality difference (95% CI)a | Vasopressor days (95% CI)a |
|---|---|---|
| SEP-1 bundle | 0.10 (−2.41 to 2.61) | 0.26 (0.09 to 0.43)b |
| Blood cultures | −5.01 (−10.9 to 0.91) | −0.44 (−0.65 to −0.02)b |
| Serum lactate level testing | −2.68 (−6.46 to 1.09) | −0.004 (−0.31 to 0.30) |
| Broad-spectrum intravenous antibiotic treatment | −3.83 (−7.62 to −0.04)b | −0.45 (−0.78 to −0.12)b |
| Intravenous fluid treatment | −0.57 (−6.10 to 4.95) | −0.23 (−0.71 to 0.24) |
Abbreviation: SEP-1, Early Management Bundle for Severe Sepsis/Septic Shock.
a
Outcomes are reported as the differences between treated and untreated. Risk of mortality difference is expressed in terms of percentage points.
b
Statistical significance defined as 2-sided P < .05.